Compare EDAP & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDAP | CDXS |
|---|---|---|
| Founded | 1979 | 2002 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.6M | 141.8M |
| IPO Year | 1997 | 2010 |
| Metric | EDAP | CDXS |
|---|---|---|
| Price | $4.13 | $1.30 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 76.0K | ★ 960.7K |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,853,925.00 | $52,932,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | $2.67 | $5.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.61 | N/A |
| 52 Week Low | $1.21 | $1.32 |
| 52 Week High | $4.29 | $4.96 |
| Indicator | EDAP | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 32.04 |
| Support Level | $3.44 | $1.61 |
| Resistance Level | $4.28 | $1.89 |
| Average True Range (ATR) | 0.35 | 0.12 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 83.19 | 3.31 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.